Literature DB >> 26114819

Keratopathy in Autoimmune Polyendocrinopathy Syndrome Type 1.

Aude Couturier1, Pascale Saugier-Veber, Jean-Claude Carel, Jérôme Bertherat, Antoine P Brézin.   

Abstract

PURPOSE: To report the spectrum of phenotypes in patients with autoimmune polyendocrinopathy syndrome type 1 (APS1)-related keratopathy.
METHODS: In this retrospective observational case series, 6 patients followed for APS1 were included. Data collected included family history, age at presentation, and systemic and ophthalmic manifestations. The 14 coding exons of the autoimmune regulator (AIRE) gene were sequenced.
RESULTS: The age at the onset of keratopathy ranged from 4 to 20 years. The ocular symptoms varied from mild photophobia to severe pain, and visual acuity was from light perception to 20/20 Snellen equivalent. Heterogeneous corneal involvement was observed, ranging from minimal superficial punctate staining to severe stromal scarring with deep corneal neovascularization. The severity of ophthalmic findings was uncorrelated to that of systemic manifestations. The genetic analyses identified 2 novel mutations (c.173C>A in exon 2 and c.892G>T in exon 8) and 4 known mutations (c.62C>T in exon 1, c.415C>T in exon 3, c.1096-1G>A in intron 9, and c.1193delC in exon 10) in the AIRE gene. In patients with identical AIRE mutations, including within a sib-pair, heterogeneous phenotypes were observed.
CONCLUSIONS: Keratopathy can be an early and severe manifestation of APS1, which contributes to the global prognosis of the disease. Its mechanisms remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26114819     DOI: 10.1097/ICO.0000000000000513

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  1 in total

1.  Neurotrophic keratitis in autoimmune polyglandular syndrome type 1: a case report.

Authors:  Po-Ying Wu; Huai-Wen Chang; Wei-Li Chen
Journal:  BMC Ophthalmol       Date:  2021-01-07       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.